Rationale and design of the Chinese Atrial Fibrillation Registry Study

• DOI: 10.1186/s12872-016-0308-1
• Publication Date: 2016-06-07T11:33:04Z
• Authors: Xin Du; Changsheng Ma; Jiahui Wu; Songnan Li; Man Ning; Ribo Tang; Xueyuan Guo; Deyong Long; Ronghui Yu; Caihua Sang; Chenxi Jiang; Ting Zhang; Jianhong Pan; Xiaohui Liu; Jianzeng Dong; Gregory Y. H. Lip
• Keywords: Angiology; Clinical endpoint

Robust data on the contemporary management of atrial fibrillation (AF) patients in China are limited. Importantly current practice AF has changing dramatically recent years. Data from a large registry study will enable us to evaluate uptake and outcomes with different therapies Chinese population.The Atrial Fibrillation Registry (CAFR) aims enroll 20,000 consecutive 32 tertiary non-tertiary hospitals Beijing, China, follow up these every 6 months until 2020. Key collected includes basic sociodemographic information, symptoms signs, medical history, results physical examination laboratory test, details treatments personal insurance status. For who consent, 5 ml blood sample be stored at -80 °C for future analyses biomarkers. At each month visit, relating clinical collected. randomly selected 10 % internally validated their raw source data. Ischemic stroke events adjudicated by an independent endpoint committee.CAFR one largest registries Asian (and patients), as well providing longest up. This would provide valuable opportunity 'real world' epidemiology insights into outcomes) management.Chinese Clinical Trial ChiCTR-OCH-13003729 . Registered 22 October 2013.